Linerixibat is a medicine that helps ease the strong itching that can come with primary biliary cholangitis (PBC), a liver disease. It is a pill taken by mouth. It works by helping the body get rid of more bile acids, which are linked to the itch.
Every report comes from a Lived member, sent anonymously.
Have you tried Lynavoy (Linerixibat) for Biliary Cirrhosis?
Linerixibat, sold as Lynavoy, is a prescription tablet for adults with primary biliary cholangitis (PBC) who have itching caused by the disease. PBC is a long-term condition in which the small bile ducts inside the liver become inflamed and are gradually destroyed, so bile builds up. That backup, called cholestasis, commonly causes itching, which can be severe enough to disrupt sleep. Approved in the US in 2026, linerixibat is the first medicine approved by the FDA specifically for this itch. It treats the itch, not the liver disease itself. People taking it usually stay on their regular PBC treatment, most often ursodiol (also called UDCA), which works to slow the disease. In the main study, nearly everyone was also taking ursodiol, and about half were using other itch treatments too.
Bile acids are made in the liver and released into the intestine to help digest fat. Normally most of them are pulled back into the bloodstream near the end of the small intestine and returned to the liver to be used again. Linerixibat blocks the pump that does this recapture, called the ileal bile acid transporter (IBAT), so more bile acids leave the body in the stool and fewer circulate in the blood. In PBC, bile acids and related substances that build up are thought to help drive the itch. Blood bile acid levels fall within a day of starting the medicine. Exactly why this relieves itching is not fully understood, and lowering bile acids does not mean the same amount of relief for everyone.
Linerixibat comes as a 40 mg tablet taken by mouth twice a day. Swallow each tablet whole, at least 30 minutes before any food or drink other than water, so it is usually taken before breakfast and before the evening meal. If a dose is missed, take it as soon as you remember, still at least 30 minutes before the next meal. If more than 6 hours have passed, skip that dose and take the next one at the usual time. Do not take two doses to make up for a missed one.
Diarrhea is the most common side effect and is expected from how the drug works, since more bile acids reach the large intestine. In the main study it affected about 6 in 10 people taking linerixibat, compared with about 2 in 10 on placebo. It usually began in the first three weeks and was mostly mild or moderate. Stomach pain, bloating, indigestion, reflux, nausea, headache, dizziness and joint pain were also more common than with placebo. About 14% of people stopped the medicine because of side effects, mainly diarrhea, stomach pain or changes in liver tests. Diarrhea that does not settle, or signs of dehydration such as dizziness, extreme thirst or passing very little urine, are reasons to contact the care team; the medicine may need to be paused or stopped. Easy bruising, nosebleeds, bleeding that lasts longer than usual, or blood in the stool should also be reported, as should any broken bone.
Linerixibat should be avoided in people whose cirrhosis has become decompensated, meaning the liver can no longer keep up and problems such as fluid buildup in the belly (ascites), bleeding from enlarged veins in the esophagus or stomach (variceal bleeding), or confusion from liver failure (hepatic encephalopathy) have occurred. It has not been studied in that group. It has also not been studied in children. Because it changes how bile acids move through the gut, linerixibat can reduce absorption of the fat-soluble vitamins A, D, E and K. PBC itself can already lower these vitamins and weaken bones. Before starting and periodically during treatment, the care team checks vitamin A, D and E levels and an INR (international normalized ratio, a clotting test that reflects vitamin K), and prescribes supplements if levels run low. A shortage of vitamin K can make bleeding more likely, and medicines in this class have been linked to bone fractures, so bone health is also watched. These vitamin checks matter during pregnancy and breastfeeding as well, since the developing baby depends on them. Liver blood tests are taken before treatment and monitored afterward. In the main study, liver test increases were more common with linerixibat, and if they persist the medicine is stopped. Cholestyramine (Questran) and similar bile acid binding resins, which are sometimes used to treat PBC itch, can bind linerixibat in the gut and block its effect. Take linerixibat at least 4 hours before or 4 hours after a resin dose.
Some people notice less itching within the first two weeks. In the 24-week main study, itch scores on a 0 to 10 scale started around 7 and fell by an average of about 2.9 points with linerixibat, compared with about 2.2 points with placebo. That means the added benefit over placebo was modest on average, though some people improve more than others, and itch-related sleep disruption also eased slightly more than with placebo. Results beyond 24 weeks are not yet described in the US label. Diarrhea, when it happens, most often starts in the first few weeks, so that is when the care team may need to hear how things are going. Ongoing treatment involves regular blood tests for liver function and vitamin levels, alongside routine PBC follow-up. If itching does not improve enough, or side effects outweigh the benefit, the medicine can be stopped and other itch treatments considered.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Lynavoy (Linerixibat), what you've noticed, or ask the community a question.